Last reviewed · How we verify
NCT07348913
Impact of Regular Low-Frequency Hemoperfusion on Medium- to Long-Term Prognosis in Maintenance Dialysis Patients
trial in Regular Low-Frequency Hemoperfusion in 879 participants. Completed in 31 December 2024.
31 December 2024
Quick facts
| Lead sponsor | Yunfeng Xia |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 879 |
| Start date | 1 January 2015 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Conditions studied
- Regular Low-Frequency Hemoperfusion — all drugs for Regular Low-Frequency Hemoperfusion →
- Medium- to Long-Term Prognosis — all drugs for Medium- to Long-Term Prognosis →
- Maintenance Dialysis Patients — all drugs for Maintenance Dialysis Patients →
- Retrospective Study — all drugs for Retrospective Study →
Sponsor
Yunfeng Xia — full company profile →
Who can join
18 and older, any sex, with Regular Low-Frequency Hemoperfusion or Medium- to Long-Term Prognosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective: To investigate the effect of regular low-frequency hemoperfusion on all-cause mortality and cardiovascular/cerebrovascular mortality risk in maintenance hemodialysis (MHD) patients. Methods: Data from MHD patients over the past 10 years at our blood purification center were retrospectively collected. Patients were divided into a hemoperfusion group (receiving regular low-frequency hemoperfusion once monthly) and a non-hemoperfusion group. Propensity score matching (PSM) was used to balance baseline characteristics. Differences in cumulative all-cause and cardiovascular/cerebrovascular mortality between the two groups before and after matching were compared. A competing risk model was employed to analyze mortality risk.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07348913
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Yunfeng Xia trials
Trials by the same sponsor.
- NCT07291154 — Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy · NA · recruiting
- NCT07199504 — A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole · Phase 2, PHASE3 · active not recruiting
- NCT06568835 — The Effect of Active Exercise on Maintenance Haemodialysis Patients · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07348913 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yunfeng Xia
- Last refreshed: 16 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07348913.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing